CARLSBAD, CA - Palisade Bio, Inc. (NASDAQ: PALI), a clinical-stage biopharmaceutical company with a market capitalization of ...

(RTTNews) - Palisade Bio, Inc. (PALI), Thursday announced a preliminary data from five planned Single Ascending Dose cohorts, showing that PALI-2018 was well-tolerated among doses ranging from 15 mg ...

Company on track to report topline data in first half of 2025Positive preliminary data from all five single ascending dose (SAD) cohorts ranging ...

Omvoh's approval as a treatment for Crohn's disease was based on results from a study in which 53% of patients treated with the drug achieved clinical remission, and 46% of patients had visible ...

Eli Lilly (NYSE:LLY) has received FDA approval for its drug Omvoh, also known as mirikizumab-mrkz, for the treatment of ...

The CEO of Spyre, Cameron Turtle, emphasized the company's progress in 2024, including entering first-in-human studies with ...

Tulisokibart, a TNF–like cytokine 1A monoclonal antibody, has demonstrated significant potential in inducing clinical ...

Learn why white rice, mashed potatoes, fruits without the skin, and other low-fiber and low-residue foods are your best bet ...

For patients with ulcerative colitis, upadacitinib is associated with improved disease-specific outcomes compared with tofacitinib.

For patients with ulcerative colitis, upadacitinib is associated with improved disease-specific outcomes compared with tofacitinib.

MK-6194 is under clinical development by Merck and currently in Phase II for Ulcerative Colitis. According to GlobalData, Phase II drugs for Ulcerative Colitis have a 45% phase transition success rate ...